Frequency of TERT Promoter Mutations in Prostate Cancer

Objective: Recently, recurrent mutations within the core promoter of the human telomerase reverse transcriptase (TERT) gene generating consensus binding sites for ETS transcription factor family members were described in melanomas and other malignancies (e.g. bladder cancer, hepatocellular carcinoma). These mutations were discussed as early drivers for malignant transformation. In prostate cancer (PrCa) TERT expression has been associated with a poor prognosis and higher risk for disease recurrence. The underlying mechanisms for high TERT expression in PrCa have still not been clarified. To date, data on TERT promoter mutation analysis in PrCa are sparse. Therefore, we performed sequence analysis of the core promoter region of the TERT gene in an unselected cohort of prostate tumors. Methods: Sections from 167 formalin-fixed, paraffin-embedded and cryopreserved prostate tumors were microdissected and used for DNA isolation. The mutation hotspot region within the TERT core promoter (-260 to +60) was analyzed by direct Sanger sequencing or SNaPshot analysis. Results: All cases were analyzed successfully. Mutations within the core promoter of the TERT gene were not detected in any of the cases with all tumors exhibiting a wild-type sequence. Conclusion:TERT core promoter mutations reported from several other malignancies were not detected in our unselected cohort of PrCa. These data indicate that alterations within the core promoter of the TERT gene do not play an important role in prostate carcinogenesis.

[1]  J. Squire,et al.  Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. , 2014, Cancer genetics.

[2]  Ximing J. Yang,et al.  High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins , 2014, Journal of Hematology & Oncology.

[3]  Miguel Melo,et al.  Telomerase promoter mutations in cancer: an emerging molecular biomarker? , 2014, Virchows Archiv.

[4]  R. Hrdličková,et al.  Multiple Tumor Suppressor microRNAs Regulate Telomerase and TCF7, an Important Transcriptional Regulator of the Wnt Pathway , 2014, PloS one.

[5]  Z. Cai,et al.  Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. , 2014, European urology.

[6]  M. Knowles,et al.  Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. , 2014, European urology.

[7]  Ç. Avcı,et al.  Disodium pentaborate decahydrate (DPD) induced apoptosis by decreasing hTERT enzyme activity and disrupting F-actin organization of prostate cancer cells , 2014, Tumor Biology.

[8]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[9]  Peter Kraft,et al.  Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression , 2013, Human molecular genetics.

[10]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[11]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[12]  Marcel J. T. Reinders,et al.  Detecting recurrent gene mutation in interaction network context using multi-scale graph diffusion , 2013, BMC Bioinformatics.

[13]  Trygve O Tollefsbol,et al.  Regulation of the human catalytic subunit of telomerase (hTERT). , 2012, Gene.

[14]  Suzanne Chambers,et al.  Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study , 2011, Nature Genetics.

[15]  I. Chu,et al.  Short rare hTERT-VNTR2-2nd alleles are associated with prostate cancer susceptibility and influence gene expression , 2010, BMC Cancer.

[16]  Yubin Ge,et al.  Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment , 2010, Molecular Cancer Therapeutics.

[17]  F. Grillone,et al.  Tumours of the prostate , 2010, BMC Geriatrics.

[18]  K. Shimada,et al.  Phosphorylation Status of Fas-Associated Death Domain-Containing Protein Regulates Telomerase Activity and Strongly Correlates with Prostate Cancer Outcomes , 2009, Pathobiology.

[19]  Ina Prade,et al.  Wild‐type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  A. Meeker,et al.  Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. , 2006, Urologic oncology.

[21]  Mitsutoshi Nakamura,et al.  Phosphorylation status of Fas‐associated death domain‐containing protein (FADD) is associated with prostate cancer progression , 2005, The Journal of pathology.

[22]  A. Marx,et al.  World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .

[23]  B. Armbruster,et al.  In vivo regulation of hTERT expression and telomerase activity by androgen. , 2003, The Journal of urology.

[24]  B. Wullich,et al.  Telomerase Activity and Telomerase Subunit Gene Expression Levels Are Not Related in Prostate Cancer: A Real-Time Quantification and In Situ Hybridization Study , 2003, Laboratory Investigation.

[25]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.

[26]  J. Barrett,et al.  The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions , 2002, Oncogene.

[27]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[28]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[29]  D. Schadendorf,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .